Ukusetyenziswa kweklinikhi yeSalmon PDRN kwi-Aesthetic Medicine: Ngaphaya kwe "Salmon Sperm" Ingxelo 

Inkcazelo yeMeta
Phonononga isayensi emva kweSalmon PDRN yokubuyisela emva kwe-laser, ulawulo lokudumba, kunye nezisombululo zokulwa nokuguga. Isikhokelo esisebenzayo seempawu zokhathalelo lwesikhumba kunye neengcali zonyango zobuhle.

Intshayelelo: Kutheni iPDRN ifuna ukuJonga okwesibini

NgoJanuwari 2026, isihloko saphinda sathimba ingqalelo yehlabathi lobuhle: "Inyaniso malunga noBuso beSalmon Sperm" . Yayichukumisa, intsholongwane, kwaye-njengamaxesha amaninzi entsholongwane-yayiphosa inqaku ngokupheleleyo.

Emva kwegama elixhokonxayo kukho elinye lawona makhulu ngoomatshini ezahlukeneyo ii-biomolecules ezihlaziyayo ukungena iyeza lobuhle kumashumi eminyaka. I-Polydeoxyribonucleotide (PDRN) ayisiyonto nje enye i-hydrating ingredient okanye i-collagen booster. Isebenza nge iindlela ezimbini, ezihambelanayo-I-extracellular receptor activation kunye ne-intracellular nucleotide salvage-ukuba kungabikho esinye isithako sobuhle siphindaphinda.

Ukanti ukubhideka kusaqhubeka. Oogqirha badibanisa i-PDRN kunye ne-polynucleotide (PN). Brands market "DNA skincare" ngaphandle kokuqonda ukunqunyulwa kwemolekyuli. Abalawuli e-China nase-US bahamba ngesantya esahlukileyo, bedala iintloko ezibuhlungu zokuthotyelwa kwemveliso yehlabathi jikelele .

Eli nqaku libhalelwe abaqulunqi, abalawuli beklinikhi, kunye namaqhinga ohlobo abafuna ukudlula kwi-hype. Siyaphonononga:

• I Indlela yokwamkela i-A2A eyahlula i-PDN kwi-PN kunye nezinto zokukhula

• Ubungqina benkqubo ethile kwi-post-laser kunye ne-microneedling applications

• Uhlaziyo lwamagama-kutheni i-"Marques Polynucleotide Cutoff" itshintsha indlela obhala ngayo iimveliso

• Amanyathelo olawulo e-China kunye nokuba bathetha ukuthini ngo-2026-2027 ukungena kwimarike

Akukho sensationalism. Akukho mabango "ommangaliso". Umqondiso nje, owahlulwe kwingxolo.

1. Ukuchaza i-Molecule: Kutheni i-PDRN kunye ne-PN zingatshintshi

1.1 Ungenelelo ngo-2025 lweNomenclature

Kwiminyaka engamashumi amathathu, uncwadi lobuhle obusetyenziswayo I-PDN kwaye PN ngokutshintshisanayo. Zombini zithathwe kwi-DNA. Zombini zivela kwi-salmon okanye kwi-trout. Zombini zisetyenziswa kwiinaliti kunye nezihloko.

Oku bekuyingxaki. Oogqirha bakhethe iimveliso ezisekelwe kudumo lwebrendi endaweni yokufaneleka kwemolekyuli, ekhokelela kwiziphumo ezisezantsi kunye noncwadi lwezonyango olubhidekileyo .

NgoJanuwari 2025, iqela lophando lwamazwe ngamazwe elikhokelwa nguMarques et al. icetywe isisombululo solwakhiwo: iMarques Polynucleotide Cutoff.

• I-PDN (Polydeoxyribonucleotide): Ubunzima bemolekyuli < 1500 kDa. Amatyathanga amafutshane. I-A2A receptor agonist. Indlela yokuqala: umqondiso we-pharmacologic + nucleotide salvage.

• PN (Polynucleotide): Ubunzima bemolekyuli ≥ 1500 kDa. Amatyathanga amade. Yenza i-viscous hydrogel. Indlela yokuqala: mechanical volumizing + hydration .

Impembelelo yonyango:
Ukuba imveliso yakho ixhomekeke ukubonakaliswa kwe-anti-inflammatory, activation fibroblast, okanye i-VEGF-mediated angiogenesis, usebenzisa i-PDRN-kungakhathaliseki ukuba ileyibhile ithini. Ukuba imveliso yakho ixhomekeke ukuzaliswa kwe-viscoelastic kunye ne-hydration eqhubekayo, usebenzisa i-PN .

1.2 Iiyantlukwano zeZakhiwo ezichaphazela iNtsebenzo

Ukuthathwa okungundoqo kwiibrendi:
Ukusebenzisa "i-PN" ukuchaza ukuqulunqwa kwe-PDRN ye-short-chain ayikona nje ukungachanekanga-kulahlekisa oogqirha malunga neendlela ezilindelekileyo kunye nobude besiphumo.

2. IiNdlela zokuSebenza: iNdlela eMabini echaza iPDRN

Ngokungafaniyo neninzi ye-aesthetic biomolecules esebenzayo iziphumo zomgca omnye, PRN isebenza nge iindlela ezimbini ezizimeleyo kodwa ezisebenzisanayo .

2.1 Indlela yokuQala: I-A2A ye-Receptor Activation

I-PDRN i-agonist ekhethiweyo ye i-adenosine A2A receptor-i-G-protein-coupled receptor ebonakaliswa kwi-fibroblasts, iiseli ze-endothelial, kunye neeseli zomzimba.

Izinto ezibangela ukuba zibophe:

• ↑ inkampu (i-cyclic adenosine monophosphate) -umqondiso we-intracellular ukuba kusebenze i-A2A

• ↓ NF-κB ukutshintshwa-ukunciphisa ukubhaliswa kwe-cytokines e-pro-inflammatory (TNF-α, IL-1β, IL-6)

• ↑ VEGF (i-vascular endothelial growth factor) -ikhuthaza i-angiogenesis kunye ne-perfusion yezondlo kwizicubu zokuphilisa

• ↑ Ukwenziwa kweCollagen I/IIII-Mediated via downregulation of MMP-1 kunye nolawulo lwe-TGF-β

Ubungqina obuvela kwimihlaba emeleneyo:
A 2025 ScienceDirect Uphononongo kwi-ulcerative colitis yaqinisekisa ukuba ulawulo ngokubambisana lwe-DMPX (umchasi we-A2A) kupheliswe ngokupheleleyo I-PDRN ye-anti-inflammatory kunye ne-VEGF-upregulating effects. Le ikwayindlela enye ye-receptor eyenziwa kwidermal fibroblasts .

Uguqulo lwezonyango:
Xa i-PDRN ihanjiswa kulusu oluphazamisekileyo-nokuba ngenaliti, i-microneedling, okanye i-laser-assisted infusion-it ibonakalisa ngenkuthalo izicubu ukuba zitshintshe ukusuka kwi-inflammation ukuya kwimodi yokulungisa eyandayo. Oku ayisosondlo sokwenziwa. Oku kunjalo ungenelelo lwe-pharmacologic .

2.2 Indlela yesiBini: Ubonelelo lweNucleotide yeSalvage Pathway

Izicubu ezonzakeleyo kunye ne-hypoxic zijongene nengxaki yamandla. De novo nucleotide synthesis—indlela yokusilela yeseli yokwakha izandulela ze-DNA—ifuna ioksijini eninzi kwaye iyabiza ngamandla .

I-PDN ibonelela ngenye indlela.

Xa i-PDRN ifumana ukuthotywa kwe-enzymatic, iyakhupha nucleosides bioavailable kunye nucleotides ukuba bangene kwi indlela yokusindisa. Oku kuphinda kusetyenziswe iziseko esele zenziwe ngokuthe ngqo kwi-DNA synthesis, igqitha indlela ebiza amandla e-de novo .

Kutheni oku kubalulekile kwiyeza lobuhle:

• Ulusu lwe-post-laser lu Uxinzelelo lwemetabolism kunye ne-hypoxic

• I-Fibroblasts idinga i-nucleotides ukuze yande kwaye idibanise i-collagen

• I-PDN ibonelela imathiriyeli ekrwada kwangoko ngelixa ngaxeshanye usayina nge-A2A ukuya lawula oomatshini bokulungisa

Asikho esinye isithako sobuhle esenza zombini.

3. Izicelo zeklinikhi: Ubungqina ngeNkqubo

3.1 I-Post-Laser Resurfacing: Esona sibonakaliso siXhaswa kakhulu

Ingxaki:
I-Fractional laser resurfacing idala ukulimala kobushushu obulawulwayo. Ngelixa isebenzayo kuhlengahlengiso, iyakhuthaza ixesha elide le-erythema, i-edema, kunye nexesha lokunciphisa isigulane. Ngokwembali, oogqirha bayamkela le nto njengento engenakuthintelwa .

Isisombululo sePDN:
Uphononongo lwemodeli yeempuku luka-2017 nguYu noLee lubonise oko Amanxeba e-laser anyangwa nge-PDRN abonise ukwanda kakhulu kweeseli ze-VEGF kunye ne-CD31-positive microvessels xa kuthelekiswa nolawulo. I-re-epithelialization ikhawuleze. Ukudumba kwehla ngokukhawuleza .

Iperile yonyango:
I-PDRN "ayithinteli" ukulimala kwe-laser-it icinezela isigaba sokuvuvukala kwaye yandisa isigaba sokwanda. Abaguli basabomvu, kodwa bona phuma bubomvu ngokukhawuleza .

Ukuqonda kweprotocol ka-2026:
Iiklinikhi eziphambili zokuhlaziya zase-US ngoku zisebenzisa i-PDRN njenge isongezo esikhethiweyo ukuphakamisa ubuso kunye neenkqubo ze-laser-kungekhona "njengommangaliso" ozimeleyo, kodwa njenge-a isixhasi sesandi sebhayoloji yendawo yokuphilisa.

3.2 I-Microneedling nge-PDRN: I-Device-Assisted Synergy

I-Microneedling iyadala imijelo emincinci emincinci edlula umqobo we-stratum corneum. Oku asikokunikela intetho nje—i i-micro-innjury ngokwayo ivula iiplatelet kwaye ifune iiseli zokulungisa .

Xa i-PDN i ifakwe ngexesha le-microneedling, iindlela ezimbini zilungelelaniswa:

1. Ngokwenyama: I-PDRN ifikelela kwi-dermis ngaphandle kokuthembela kwiifomyula "ze-transdermal" ezingathandabuzekiyo

2. Ibhayoloji: Ukudumba okubangelwa yiMicroneedling yi imodareyithwe ngenkuthalo nge-PDRN's A2A agonism

Iziphumo eziqwalaselweyo (zixelwe kwikliniki):

• Ukunciphisa ixesha le-erythema emva kwenkqubo

• Ukubuyela ngokukhawuleza kwi-makeup (kaninzi iiyure ezingama-24 vs. 48–72)

• Uphuculo lokuthungwa kwenkqubela phezu kweeseshini ze-3-6

Isilumkiso:
I-PDN ye-Topical ifakwe kwi-skin ecocekileyo ngaphandle Unikezelo oluncedisiweyo luhlala lusebenza ngendlela engaqinisekiswanga. Oogqirha besikhumba ekwenziwa udliwano-ndlebe nabo ngoFebruwari 2026 bavakalise ukuthandabuza ukuba izibonelelo ezibonakalayo ezivela “ekhaya” kwiiserum zePDRN ziphuma kwiPDRN ngokwayo—izithako ezixhasayo zinokuba ziiarhente ezisebenzayo .

3.3 Izicelo ezichasene nokudumba: Ngaphaya kweNkqubo

Ukuvutha okungapheliyo kwinqanaba eliphantsi libonakalisa ulusu olugugayo, ulusu olubuthathaka, kunye ne-rosacea-prone phenotypes. Ii-anti-inflammatory agents (i-corticosteroids, i-calcineurin inhibitors) ziyasebenza kodwa azilufanelanga ulondolozo lwexesha elide .

I-PDN inikezela nge non-steroidal, physiologically regulated i-anti-inflammatory mechanism.

Umjelo wobungqina:

• Ukuqaliswa kwe-A2A icinezela i-NF-κB, ukunciphisa ukubhalwa kwe-TNF-α kunye ne-IL-6

• I-IL-10 (i-cytokine echasayo) ilawulwa

• Ukuqaliswa kweVEGF ixhasa ingqibelelo ye-vascular, ukunciphisa i-erythema eqhubekayo

Ujoliso lwezonyango:
Izigulana ezingakwaziyo ukunyamezela i-retinoids ngenxa ye-fragility yomqobo inokuxhamla I-PDRN njenge-arhente yolondolozo elungiselela ukulungiswa, isetyenziswe ngokudityaniswa nokukhukula okuthambileyo kunye nokhuseleko lwefoto .

4. IMeko-mhlaba eLawulayo: iSimo sika-2026 kunye neempembelelo zeQhinga

4.1 ETshayina: IMilestones ye-NMPA

Ukusukela ngo-Epreli 2025, iinkampani ezisixhenxe kuphela sele ugqibile ubhaliso lwefayile yesixhobo sonyango sePDRN kunye neNMPA yaseTshayina. ILingmei Biotechnology (Hubei Lingmei) yaba yi eyesixhenxe ngoAprili 16, 2025.

Umgca wexesha:

• Ubhaliso lweefayile eziphambili: 2025 Q2

• Ukugqitywa kolingo lwezonyango: Kuqikelelwa ngo-2025 Q3

• Ulwamkelo oluqikelelweyo lwesixhobo sonyango: 2026 Q4

Kuthetha ukuthini oku:

• Akukho PDRN ethobelayo etofwayo ekhoyo ngoku eTshayina

• Iimveliso ezithengiswayo zithembele ukubhaliswa kwezithambiso okanye imida yorhwebo ye-e-commerce

• Iimpawu zokuqala ezinezixhobo ezivunyiweyo zodidi lwesithathu ziya kubamba ukuqala kwesabelo semarike ngasekupheleni kuka-2026

Uphuhliso olunxuseneyo:
I-SEOHO LAB igqityiwe ukubhaliswa kwelayisensi yococeko ye-NMPA ye Isingredient PRN ngoDisemba 2025, ukususa imiqobo yokuthumela ngaphandle i-cosmetic-grade Iimveliso zePDN .

Ukuthatha ngobuchule:
I-PDRN etofwayo kunye ne-PDRN ye-topical ziindlela zolawulo ezihlukeneyo. Iimpawu ezijolise kumajelo ezonyango kufuneka zibeke phambili Ukubhaliswa kwesixhobo seClass III. Iibrendi ezijolise kwiitshaneli zabathengi zinokuqhubeka nge Isaziso sezithambiso ze-NMPA, kodwa kufuneka sikuphephe ukwenza amabango afana neziyobisi .

4.2 EUnited States: Isimo se-FDA

Akukho mveliso ye-PDRN etofwayo ivunywe yi-FDA ukuze isetyenziswe ngobuhle .

Ukusetyenziswa kweklinikhi kwenzeka ngaphandle kweleyibhile, ngoogqirha abathi:

• Ngenisa iimveliso ngaphandle kokukhululwa kokusetyenziswa komntu

• I-PDRN edibeneyo kwiindawo zekhemesti

• Sebenzisa i-microneedling-assisted topical delivery (engabandakanyi ukusetyenziswa okutofwayo)

Ukhathalelo lwesikhumba lwePDN ilawulwa njengento yokuthambisa kwaye ayifuni imvume yangaphambili ye-FDA. Nangona kunjalo, i I-FDA ayizange iseke i-monograph ye-PDRN, kwaye imigangatho yobunzima bemolekyuli ayikho—okuthetha ukuba iimveliso ezimbini ezibhalwe “PDRN serum” zinokuqulatha amaqhekeza ahlukeneyo ahlukeneyo .

5. Iingqwalasela zokuqulunqa iiBrand kunye nabavelisi

5.1 Ubunzima beMolekyuli: Uguquko olufihlakeleyo

I-Marques Cutoff (1500 kDa) yi umgangatho wamagama, hayi a ukucaciswa koqulunqo. Ukusebenza kwezonyango kuxhomekeke ekusasazeni amaqhekeza, hayi nje umndilili wobunzima bemolekyuli .

Ubungqina obuvela ku-2018:
Hwang et al. wabonisa ukuba uluhlu olusebenzayo lweziqhekeza zePDN lubalulekile kumgangatho wokuphulukisa isilonda. Ifutshane kakhulu: ukuthotywa ngokukhawuleza, akukho phawu oluzinzileyo. Inde kakhulu: ukuncitshiswa kwe-A2A bioavailability, ukuziphatha ngoomatshini kufana ne-PN .

Isikhokelo soqulunqo:

• Isicelo uhlalutyo olupheleleyo lokusasazwa kweqhekeza kubaboneleli ngezinto ezikrwada

• Chala iinkcukacha ezidwelisa kuphela “umndilili wobunzima bemolekyuli”

• Ngemiqondiso yokulungisa emva kwenkqubo, amaqhekeza aphakathi (50–500 kDa) inokubonelela ngothethathethwano lwe-A2A olululo

5.2 Inkqubo yonikezelo: Imfuneko yokufunxa

PRN nguye i-hydrophilic kunye ne-high-molecular-weight xa kuthelekiswa nezinto ezisebenzayo zokuthambisa zesintu. Usasazeko olungagungqiyo ngestratum corneum luncinci .

Izicwangciso zonikezelo eziqinisekisiweyo:

Intsingiselo yebhrendi:
Ukuba usungula "i-serum yePDN yasekhaya," kufuneka nokuba:

1. Tyala imali kwi i-bioavailable fragment engineering (amaqhezu e-MW asezantsi kakhulu), okanye

2. Yivume loo nto izithako zesithuthi (i-humectants, i-anti-inflammatories) iqhuba izibonelelo zokuthambisa ngokukhawuleza, kunye ne-PDRN igalelo iziphumo ezikhulayo zokuvuselela kwiiveki ukuya kwiinyanga .

6. Imida esakhulayo kunye nemibuzo engasonjululwanga

6.1 I-Vegan / i-Recombinant PDRN

I-PDN yesiNtu yi i-salmon ephuma. Iinkxalabo zokusingqongileyo, iinqobo zokubonelela ngeenkonzo, kunye nokuchasana nokwaliwa kweentlanzi kunyuse umdla ezinye iindlela ezisekwe kwisityalo kunye nokuvundiswa .

Ubume bangoku:

• IVegan PDRN (i-algae-derived, synthetic biology) ifumaneka ngokurhweba

• Ubuchwephesha bu yenzelwe ukulinganisa A2A agonism

• Idatha yeklinikhi yexesha elide ayikabikho

Umbono weDermatologist:
"Iinguqulelo ze-vegan zitsala i-levers efanayo eluswini kwaye zibonelela ngezibonelelo ezifanayo njenge-salmon yemveli ye-PDRN, kodwa abanayo idatha yeklinikhi yexesha elide ibaxhasayo okwangoku." — UNicole Lee, MD

6.2 I-PDN kwiiNyango eziDityanisiweyo

Ikamva lePDN linokwenzeka indibaniselwano, hayi i-monotherapy.

Izibini ezisakhulayo:

• PDRN + Exosomes: Inkqubo ye-AnteAGE's P.E.A.R.L idibanisa iPDRN kunye neemolekyuli zokubonisa i-exosome kwisicelo se-post-microneedling

• PDRN + Hyaluronic Acid: Ukuphononongwa kwizicelo ezidibeneyo kunye nedermal; I-synergy ebonwe kwi-fibroblast proliferation

• I-PDRN + Imiba yokuKhula: Intsebenziswano kwithiyori; idatha epapashiweyo encinci

Ingqiqo yeklinikhi:
I-PDN ibonelela i-nucleotide substrate kwaye Umqondiso we-A2A. I-Exosomes kunye nezinto zokukhula zibonelela imiyalelo eyongezelelweyo ye-cytokine. Ezi zi ehambelanayo, ayifuneki .

6.3 INguqu yeNomenclature: Impembelelo yoRhwebo

I-Marques Cutoff i ngaphantsi konyaka omnye ubudala. Ukwamkelwa kwiifayili ezilawulayo, i-pharmacopeia, kunye neenkcukacha zorhwebo kuya kuthatha ixesha.

Umngcipheko weempawu:

• Ukuqhuba uleyibhelishe i-medium-chain PDRN njenge "PN" inokumema uphononongo lolawulo njengoko iinkcazo ziqina

• Ukufaka ibango elithi "PDRN" ngamaqhekeza angaphezu kwe-1500 kDa iphikisana nomgangatho ovelayo

• INCI nomenclature ayikahlaziywa; ubuchule borhwebo buya kuthanda abamkeli bokuqala besigama esichanekileyo

Isiphelo: I-PDN kwi-2026-2027 yoNyango lweNdawo

I-PDRN ephuma kwi-Salmon ayikho ifashoni. Iye yazinza amashumi amathathu eminyaka ekhathalelo lwezonyango kuba indlela yayo i isiseko sebhayoloji, ayixhomekekanga kwintsingiselo .

Yintoni iPDN:

• I-arhente yokuvuselela iindlela ezimbini nge ubonise i-A2A agonism kunye ne-salvage pathway bioactivity

• A i-accelerator emva kwenkqubo ixhaswa bubungqina bezilwanyana kunye noguqulo

• A isithako esahlukileyo kunye nokwahlukana okucacileyo kweemolekyuli ukusuka kwi-PN

Yintoni engeyiyo iPDN:

• "Ummangaliso" uphakamisa ubuso obuzimeleyo

• I-FDA-ivunyiwe ukuba ifakwe inaliti yobuhle eU.S.

• Imveliso esemgangathweni-imiba yokusasazwa kwamaqhekeza

Kwiingcali zonyango zobuhle:

• Vavanya iPDN njenge isihlomelo, hayi ukutshintshwa

• Beka izinto ezibalulekileyo kwindawo yokuqala unikezelo ngoncedo (i-microneedling, i-laser) ngaphezu kwesicelo se-topical esenziwayo

• Hlala unolwazi Izamkelo zeNMPA zodidi lwesithathu-Baya kubumba kwakhona imarike yaseAsia ngo-2026-2027

Ngeempawu zokhathalelo lwesikhumba:

• Phonononga i-nomenclature yakho. Ngaba uthengisa i-PDN okanye i-PN? Ngaba unokungqina oko?

• Ukuba ukuqaliswa eTshayina, yahlula izicwangciso zakho zokulawula ezitofwayo kunye nezithambiso

• Ukuba usungula i-PDRN ye-vegan, yibani elubala malunga nokungabikho kwedatha yokuthelekisa ixesha elide

Izihloko ze "salmon sperm" ziya kuqhubeka. Basoloko besenza njalo.

Emva kwabo, i-biomolecule esemthethweni iqokelela ubungqina buthule, icoca inkcazo yayo, kwaye ilungiselela isigaba sayo esilandelayo sokuvuthwa kweklinikhi.

I-PDN ifanelwe ngcono kunodumo lwentsholongwane. Ifanele ukusetyenziswa okuchanekileyo, ukulebhile okuyinyaniso, kunye nokudityaniswa kwiiprothokholi ezihlaziyayo ezihlonipha amandla ayo kunye nemida yayo.